Oramed Announces Closing of $5.36 Million Registered Direct Offering

JERUSALEM, June 11, 2015 /PRNewswire/ Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a developer of oral drug delivery systems, today announced the closing of its previously-announced registered direct placement with institutional investors. Oramed has sold $5.36 million of shares of common stock at $7.50 per share. Investors have also received an oversubscription option to purchase up to an additional $7.1 million of common stock at $10.00 per share that becomes exercisable six months from today and is exercisable for twelve months. H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction. The securities described above are being offered pursuant to a shelf registration statement (File No. 333-193557), which was declared effective by the United States Securities and Exchange Commission ( SEC ) on April 10, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor s


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: